Prophylactic VSTs: a promising start but still work to do

Caitlin W Elgarten^{1

2}, Michael Grimley^{3

4}

Affiliations

¹ Division of Oncology, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
² Department of Pediatrics, University of Pennsylvania, Philadelphia, PA.
³ Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁴ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.

Editorial

Caitlin W Elgarten et al. Blood Adv. 2024.

. 2024 Sep 10;8(17):4738-4739.

doi: 10.1182/bloodadvances.2024012978.

Caitlin W Elgarten^{1

2}, Michael Grimley^{3

4}

¹ Division of Oncology, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
² Department of Pediatrics, University of Pennsylvania, Philadelphia, PA.
³ Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁴ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.

No abstract available

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.
Dadwal SS, Bansal R, Schuster MW, Yared JA, Myers GD, Matzko M, Adnan S, McNeel D, Ma J, Gilmore SA, Vasileiou S, Leen AM, Hill JA, Young JH. Dadwal SS, et al. Blood Adv. 2024 Sep 10;8(17):4740-4750. doi: 10.1182/bloodadvances.2023011562. Blood Adv. 2024. PMID: 38593233 Free PMC article. Clinical Trial.

1. Dadwal SS, Bansal R, Schuster M, et al. Final Outcomes from a Phase 2 Trial of Posoleucel in Allogeneic Hematopoietic Cell Transplant Recipients. Blood Adv. 2024;8(17):4740–4750. - PubMed
1. Hill JA, Mayer BT, Xie H, et al. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316–2325. - PMC - PubMed
1. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13. - PubMed
1. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83. - PMC - PubMed
1. Green A, Rubinstein JD, Grimley M, Pfeiffer T. Virus-specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation. J Pediatric Infect Dis Soc. 2024;13(suppl 1):S49–S57. - PubMed